Iberiabank Corp reduced its stake in shares of Teleflex Incorporated (NYSE:TFX) by 47.9% during the second quarter, according to its most recent 13F filing with the SEC. The fund owned 1,650 shares of the medical technology company’s stock after selling 1,515 shares during the period. Iberiabank Corp’s holdings in Teleflex were worth $343,000 as of its most recent filing with the SEC.
A number of other institutional investors also recently modified their holdings of TFX. Envestnet Asset Management Inc. boosted its position in shares of Teleflex by 15.2% in the fourth quarter. Envestnet Asset Management Inc. now owns 4,012 shares of the medical technology company’s stock valued at $646,000 after buying an additional 528 shares during the period. A.R.T. Advisors LLC boosted its position in shares of Teleflex by 66.7% in the fourth quarter. A.R.T. Advisors LLC now owns 2,000 shares of the medical technology company’s stock valued at $322,000 after buying an additional 800 shares during the period. Ladenburg Thalmann Financial Services Inc. boosted its position in shares of Teleflex by 7.2% in the fourth quarter. Ladenburg Thalmann Financial Services Inc. now owns 1,450 shares of the medical technology company’s stock valued at $240,000 after buying an additional 97 shares during the period. Norges Bank bought a new position in shares of Teleflex during the fourth quarter valued at about $62,676,000. Finally, UBS Asset Management Americas Inc. boosted its position in shares of Teleflex by 118.9% in the fourth quarter. UBS Asset Management Americas Inc. now owns 72,560 shares of the medical technology company’s stock valued at $11,692,000 after buying an additional 39,419 shares during the period. Hedge funds and other institutional investors own 92.90% of the company’s stock.
Shares of Teleflex Incorporated (NYSE:TFX) opened at 207.58 on Wednesday. The firm has a market capitalization of $9.34 billion, a P/E ratio of 43.08 and a beta of 1.06. Teleflex Incorporated has a 12-month low of $136.53 and a 12-month high of $211.75. The stock’s 50 day moving average price is $201.21 and its 200-day moving average price is $187.08.
Teleflex (NYSE:TFX) last released its quarterly earnings results on Thursday, May 4th. The medical technology company reported $1.80 earnings per share for the quarter, beating analysts’ consensus estimates of $1.69 by $0.11. The business had revenue of $487.90 million for the quarter, compared to the consensus estimate of $472.81 million. Teleflex had a net margin of 11.75% and a return on equity of 16.17%. Teleflex’s revenue for the quarter was up 14.8% on a year-over-year basis. During the same quarter last year, the firm earned $1.52 EPS. On average, equities analysts expect that Teleflex Incorporated will post $8.16 EPS for the current year.
The firm also recently declared a quarterly dividend, which was paid on Thursday, June 15th. Stockholders of record on Monday, May 15th were issued a dividend of $0.34 per share. The ex-dividend date of this dividend was Thursday, May 11th. This represents a $1.36 dividend on an annualized basis and a dividend yield of 0.66%. Teleflex’s dividend payout ratio is currently 28.22%.
WARNING: This piece was originally reported by Markets Daily and is owned by of Markets Daily. If you are reading this piece on another domain, it was illegally copied and reposted in violation of U.S. and international copyright & trademark law. The correct version of this piece can be viewed at https://www.themarketsdaily.com/2017/07/12/iberiabank-corp-sells-1515-shares-of-teleflex-incorporated-tfx.html.
TFX has been the topic of several recent research reports. Zacks Investment Research upgraded Teleflex from a “hold” rating to a “buy” rating and set a $217.00 price target on the stock in a research report on Tuesday, March 14th. Deutsche Bank AG boosted their price target on Teleflex from $192.00 to $213.00 and gave the company a “buy” rating in a research report on Wednesday, March 15th. Jefferies Group LLC set a $205.00 price target on Teleflex and gave the company a “buy” rating in a research report on Saturday, March 25th. Needham & Company LLC restated a “buy” rating and issued a $224.00 price target on shares of Teleflex in a research report on Friday, May 5th. Finally, Leerink Swann boosted their price target on Teleflex from $215.00 to $220.00 and gave the company a “market perform” rating in a research report on Friday, June 9th. Two equities research analysts have rated the stock with a hold rating and five have assigned a buy rating to the stock. Teleflex has a consensus rating of “Buy” and a consensus target price of $217.00.
In other news, Director Stephen K. M.D. Klasko sold 5,200 shares of the firm’s stock in a transaction on Monday, May 15th. The shares were sold at an average price of $193.56, for a total transaction of $1,006,512.00. Following the transaction, the director now owns 12,880 shares in the company, valued at approximately $2,493,052.80. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, Director Stephen K. M.D. Klasko sold 200 shares of the firm’s stock in a transaction on Monday, July 3rd. The shares were sold at an average price of $208.10, for a total transaction of $41,620.00. Following the transaction, the director now owns 8,080 shares in the company, valued at approximately $1,681,448. The disclosure for this sale can be found here. Insiders have sold a total of 10,346 shares of company stock worth $2,038,174 in the last 90 days. 2.39% of the stock is owned by insiders.
Teleflex Company Profile
Teleflex Incorporated is a provider of medical technology products. The Company designs, develops, manufactures and supplies single-use medical devices used by hospitals and healthcare providers for diagnostic and therapeutic procedures in critical care and surgical applications. The Company operates through six segments: Vascular North America; Anesthesia North America; Surgical North America; Europe, the Middle East and Africa (EMEA); Asia, and Original Equipment Manufacturer (OEM).
Receive News & Ratings for Teleflex Incorporated Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Teleflex Incorporated and related companies with MarketBeat.com's FREE daily email newsletter.